Combined Thiamidol and Low-fluence Q-switched Nd:YAG Laser for the Treatment of Facial Hyperpigmentation
Main Article Content
Keywords
Thiamidol, Hyperpigmentation, Laser
Abstract
Background: Thiamidol (isobutylamido thiazolyl resorcinol) is a novel human tyrosinase inhibitor recently shown to be effective in the treatment of hyperpigmentation. Low-fluence Q-switched Nd:YAG 1064-nm laser (LFQS) has proven to be effective for various hyperpigmentary conditions. However, there have been no studies to date on the efficacy and safety of combined Thiamidol and LFQS treatment.
Objectives: To compare the efficacy and safety of combined Thiamidol-based serum and LFQS with LFQS monotherapy for facial hyperpigmentation.
Materials and Methods: Patients with symmetrical facial hyperpigmentation were treated with five sessions of once weekly LFQS on the whole face. One side was randomly treated with a Thiamidol-based serum formulation and the other side received a placebo cream for 12 weeks. Patients were followed for 8 weeks after the last laser treatment. Relative lightness index (RL*I), Facial Hyperpigmentation Severity Score on the Malar Area (FHSSm), patient satisfaction, recurrence, and adverse events were recorded.
Results: Twenty-four (N=24) patients completed the study. Both sides demonstrated significant reductions of mean RL*I and mean FHSSm from baseline (P < .01). At the 4th week, the Thiamidol-based serum treated side showed more improvement in mean RL*I than the placebo-treated side (62.5% vs 47.3% improvement, P < .05). The mean FHSSm on the Thiamidol-based serum treated was reduced at a significantly higher percentage than the placebo- treated side (54.4% vs 40.2% reduction, P < .05). Partial recurrence was observed on both sides. No serious side effects were noted.
Conclusion: Combined Thiamidol-based serum and LFQS therapy was more superior than LFQS monotherapy in the treatment of facial hyperpigmentation. Thiamidol-based formulations may serve as adjuvant treatment for patients with hyperpigmentation with standard therapy.
References
2. Vachiramon V, Sirithanabadeekul P, Sahawatwong S. J Eur Acad Dermatol Venereol. 2015;29(7):1339-1346.
3. Nam JH, Kim HS, Lee GY, et al. Ann Dermatol. 2017;29(4):427-432.
4. Kim EH. Case Rep Dermatol. 2017;9(2):30-34.
5. Lee Y, Choi EH, Lee SW. Dermatol Surg. 2012;38(1):31-37.
6. Seo HM, Choi CW, Kim WS. Dermatol Surg. 2015;41(1):142-148.
7. Freitag FM, Cestari TF, Leopoldo LR, et al. J Eur Acad Dermatol Venereol. 2008;22(6):655-662.
8. Grimes PE, Ijaz S, Nashawati R, et al. Int J Womens Dermatol. 2019;5(1):30-36.
9. Mann T, Gerwat W, Batzer J, et al. J Invest Dermatol. 2018;138(7):1601-1608.
10. Prignano F, Ortonne JP, Buggiani G, et al. Dermatol Clin. 2007;25(3):337-342, viii.
11. Rivas S, Pandya AG. Am J Clin Dermatol. 2013;14(5):359-376.
12. Nordlund JJ, Grimes PE, Ortonne JP. J Eur Acad Dermatol Venereol. 2006;20(7):781-787.
13. Arrowitz C, Schoelermann AM, Mann T, et al. J Invest Dermatol. 2019;139(8):1691-1698.
14. Shah SD, Aurangabadkar SJ. J Cutan Aesthet Surg. 2019;12(2):76-84.
15. Trivedi MK, Yang FC, Cho BK. Int J Womens Dermatol. 2017;3(1):11-20.
16. Kim JH, Kim H, Park HC, et al. J Invest Dermatol. 2010;130(9):2333-2335.
17. Jones CE, Nouri K. J Cosmet Dermatol. 2006;5(1):9-13.
18. Kim JE, Chang SE, Yeo UC, et al. Clin Exp Dermatol. 2013;38(2):167-171.
19. Gokalp H, Akkaya AD, Oram Y. J Cosmet Dermatol. 2016;15(4):420-426.
20. Ustuner P, Balevi A, Ozdemir M. J Cosmet Laser Ther. 2017;19(7):383-390.
21. Laothaworn V, Juntongjin P. J Cosmet Laser Ther. 2018;20(6):320-325.
22. Kwon HH, Choi SC, Jung JY, et al. J Dermatolog Treat. 2019;30(4):352-356.
23. Bansal C, Naik H, Kar HK, et al. J Cutan Aesthet Surg. 2012;5(4):266-272.
24. Kim JH, Kim DH, Kim JH, et al. J Cosmet Laser Ther. 2012;14(6):277-285.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.